What is mavacamten?

Mavacamten (mavacamten) is a new type of cardiac myosin inhibitor and an important innovation in the field of drug therapy. It is mainly used to treat adult patients with New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to significantly improve the patient's functional status and symptom performance. Hypertrophic cardiomyopathy is a complex heart disease characterized by thickening of myocardial tissue, especially the left ventricle, leading to dysfunction of the heart during contraction and relaxation.

In hypertrophic cardiomyopathy, excessive thickening of the heart muscle often causes the chamber of the left ventricle to become smaller, causing obstruction of blood flow. This obstruction not only affects the heart's ability to provide sufficient oxygenated blood to the whole body, but may also cause patients to suffer from a series of clinical symptoms such as fatigue and difficulty breathing, seriously affecting the quality of life. Mavaceta helps relieve these symptoms by selectively inhibiting myosin activity in the heart muscle and reducing myocardial contractility.

Specifically, the mechanism of action of Mavacate is to reversibly change the conformation of cardiac myosin and reduce the formation of cross-bridges between myosin and actin, thereby reducing excessive cardiac contraction. This mechanism allows the heart to better adapt when faced with stress, reducing left ventricular hypertrophy and reduced compliance. Patients usually need to take Mavakatai capsules orally once a day. This administration method is convenient and easy to do, and can effectively improve patient compliance.

Although Mavaceta has a significant effect on improving the clinical symptoms of patients with hypertrophic cardiomyopathy, there are still some potential risks and adverse reactions that need to be noted during use. Common adverse reactions include dizziness and syncope; in addition, the drug may cause heart failure, especially in high-risk patients, so a thorough evaluation should be performed before treatment.

Reference materials:https://www.drugs.com/history/camzyos.html